Philogen (PHIL) Aandelenoverzicht
Philogen S.p.A., een biotechnologiebedrijf, ontwikkelt geneesmiddelen voor oncologie en chronische ontstekingsziekten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 6/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 3/6 |
PHIL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Philogen S.p.A. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | €23.40 |
| 52 Week Hoogtepunt | €27.80 |
| 52 Week Laag | €19.56 |
| Bèta | -0.017 |
| 1 maand verandering | 13.04% |
| 3 maanden verandering | 10.90% |
| 1 Jaar Verandering | 4.00% |
| 3 jaar verandering | 56.00% |
| 5 jaar verandering | 56.63% |
| Verandering sinds IPO | 40.20% |
Recent nieuws en updates
PHIL: Softer Earnings Outlook And 2026 Board Milestones Will Shape Repricing Potential
Analysts have reduced their price target on Philogen from €26 to €23. They point to softer revenue growth expectations, a lower projected profit margin and a higher future P/E multiple as key drivers of the revision.
Clinical Pipeline And Radiopharmaceutical Expansion Will Pressure Margins And Future Earnings Potential
Catalysts About Philogen Philogen develops targeted biological and small molecule therapies, primarily for oncology and certain inflammatory diseases. What are the underlying business or industry changes driving this perspective?PHIL: 2026 Board Calendar And Steady Assumptions Will Support Future Repricing Potential
Analysts have kept their fair value estimate for Philogen steady at €26.0 per share, citing largely unchanged assumptions on the discount rate, revenue trends, profit margin and future P/E as reasons for maintaining their price target. What's in the News Board meeting scheduled for March 27, 2026, to approve the Draft Financial Statements and the 2025 Consolidated Financial Statements (company filing) Board meeting set for May 12, 2026, to approve a press release containing a quarterly report with selected information on business performance for the first quarter of 2026 (company filing) Board meeting planned for September 23, 2026, to approve the Half-Yearly Financial Report as at June 30, 2026 (company filing) Board meeting scheduled for November 12, 2026, to approve a press release with a quarterly report providing selected information on business performance for the third quarter of 2026 (company filing) Valuation Changes Fair Value: unchanged at €26.0 per share, with no adjustment to the overall fair value estimate.Recent updates
PHIL: Softer Earnings Outlook And 2026 Board Milestones Will Shape Repricing Potential
Analysts have reduced their price target on Philogen from €26 to €23. They point to softer revenue growth expectations, a lower projected profit margin and a higher future P/E multiple as key drivers of the revision.Clinical Pipeline And Radiopharmaceutical Expansion Will Pressure Margins And Future Earnings Potential
Catalysts About Philogen Philogen develops targeted biological and small molecule therapies, primarily for oncology and certain inflammatory diseases. What are the underlying business or industry changes driving this perspective?PHIL: 2026 Board Calendar And Steady Assumptions Will Support Future Repricing Potential
Analysts have kept their fair value estimate for Philogen steady at €26.0 per share, citing largely unchanged assumptions on the discount rate, revenue trends, profit margin and future P/E as reasons for maintaining their price target. What's in the News Board meeting scheduled for March 27, 2026, to approve the Draft Financial Statements and the 2025 Consolidated Financial Statements (company filing) Board meeting set for May 12, 2026, to approve a press release containing a quarterly report with selected information on business performance for the first quarter of 2026 (company filing) Board meeting planned for September 23, 2026, to approve the Half-Yearly Financial Report as at June 30, 2026 (company filing) Board meeting scheduled for November 12, 2026, to approve a press release with a quarterly report providing selected information on business performance for the third quarter of 2026 (company filing) Valuation Changes Fair Value: unchanged at €26.0 per share, with no adjustment to the overall fair value estimate.PHIL: 2026 Board Schedule Will Support Confidence In Future Repricing Potential
Analysts have kept their price target for Philogen steady at €26.0, indicating only minimal tweaks in the discount rate and forward P/E assumptions, while leaving profit margin expectations unchanged. What's in the News Board meeting scheduled for March 27, 2026, to approve the Draft Financial Statements and the 2025 Consolidated Financial Statements (company event) Board meeting set for May 12, 2026, to approve a press release containing a quarterly report with selected information on the first quarter of 2026 (company event) Board meeting planned for September 23, 2026, to approve the Half-Yearly Financial Report as at June 30, 2026 (company event) Board meeting scheduled for November 12, 2026, to approve a press release containing a quarterly report with selected information on the third quarter of 2026 (company event) Valuation Changes Fair Value: kept steady at €26.0 per share, with no change in the central valuation level.PHIL: 2026 Board Timetable Will Support Confidence In Future Upside
Analysts have left their fair value estimate for Philogen steady at €26.0. They point to only minor tweaks in the discount rate and assumed future P/E that reflect updated risk and earnings assumptions rather than a shift in their overall view. What's in the News Board meeting scheduled for March 27, 2026 to approve the Draft Financial Statements and the 2025 Consolidated Financial Statements (company filing) Board meeting set for May 12, 2026 to approve the press release that will contain the quarterly report with selected information on first quarter 2026 performance (company filing) Board meeting planned for September 23, 2026 to approve the Half-Yearly Financial Report as at June 30, 2026 (company filing) Board meeting on November 12, 2026 to approve the press release that will contain the quarterly report with selected information on third quarter 2026 performance (company filing) Valuation Changes Fair Value: Kept steady at €26.0 per share, with no change in the headline estimate.PHIL: 2026 Board Milestones Will Support Confidence In Future Upside
Analysts have made only a marginal adjustment to their valuation framework for Philogen, keeping the fair value anchor steady at around €26 while fine tuning inputs such as the discount rate, revenue growth assumptions and future P/E to reflect updated risk and earnings expectations. What's in the News Board meeting scheduled for March 27, 2026, to approve the draft financial statements and the 2025 consolidated financial statements (company event calendar).PHIL: Upcoming Trial Readouts And 2026 Milestones Will Support Upside Potential
Narrative Update on Philogen Analysts now set their price target for Philogen at €26.00, broadly in line with the prior €26 level. This reflects modestly lower discount rate and future P/E assumptions that fine tune their view of the company’s risk and valuation profile.PHIL: Future Sarcoma Trial Data Will Support Upside Potential
Analysts have modestly lifted their price target for Philogen to €26.00 per share, reflecting small tweaks to their discount rate and long term P/E assumptions, while keeping fair value otherwise unchanged. What's in the News Philogen provided an update on the FIBROSARC Phase III trial, which tests fibromun plus doxorubicin versus doxorubicin alone as first line treatment for advanced or metastatic soft tissue sarcoma.PHIL: Future Sarcoma Trial Data Will Support Upside Potential
Analysts have adjusted their price target for Philogen to €26.00. The change reflects slightly higher perceived risk through a modestly higher discount rate and a broadly unchanged outlook for margins and future P/E assumptions.PHIL: Future Sarcoma Trial Progress Will Support Upside From Current Levels
Analysts have nudged their price target on Philogen slightly higher to €26.00. This reflects unchanged assumptions on fair value, discount rate, and long term profitability, while acknowledging the resilience of the company’s margin outlook despite subdued growth expectations.PHIL: Future Trial Milestones And Buyback Activity Will Support Fair Value
Analysts have modestly raised their price target on Philogen to €26.00 per share, reflecting improved expectations for long term profit margins and valuation multiples, despite slightly lower near term revenue growth forecasts. What's in the News Philogen reported updated data from its FIBROSARC Phase III trial of fibromun plus doxorubicin in advanced or metastatic soft tissue sarcoma, with primary endpoint progression free survival and plans to present full results at scientific conferences and in a peer reviewed journal in 2026 (Key Developments).PHIL: Share Buyback and Stable Financials Will Support Current Fair Value
Narrative Update on Philogen Analysts have maintained their price target for Philogen at €26.00. They cite continued confidence in the company’s outlook despite only minor adjustments to valuation inputs.PHIL: Share Buyback and Stable Metrics Expected to Sustain Fair Value
Narrative Update: Philogen Price Target Revision Analysts have maintained Philogen's fair value estimate at €26.00. Adjustments in future revenue growth and profit margin expectations are key supporting factors for this unchanged target.Analysts Maintain €26 Target for Philogen as Buyback and Valuations Remain Stable
Analysts have maintained their price target for Philogen at €26.00 per share, citing stable expectations for key financial metrics and future performance. What's in the News Philogen completed the repurchase of 29,448 shares, representing 0.07% of total shares, for €0.66 million under the buyback program announced on May 12, 2025 (Key Developments).Late-stage Approvals Plus Sun Pharma Will Transform Oncology Despite Risks
Analysts have lowered their price target for Philogen from $28.00 to $26.00. This decision is based on revisions in revenue growth projections and a significant reduction in estimated profit margins.Philogen's (BIT:PHIL) Earnings Aren't As Good As They Appear
Despite posting strong earnings, Philogen S.p.A.'s ( BIT:PHIL ) stock didn't move much over the last week. We decided...Late-stage Approvals Plus Sun Pharma Will Transform Oncology Despite Risks
Key Takeaways Advancing late-stage therapies and strategic pharma partnerships position Philogen for recurring product sales, stronger margins, and reduced funding risk through enhanced cash flow visibility. Alignment with personalized medicine trends and a robust cash position support long-term growth, innovation, and protection of shareholder value amid rising global demand for oncology solutions.Analyst Forecasts For Philogen S.p.A. (BIT:PHIL) Are Surging Higher
Philogen S.p.A. ( BIT:PHIL ) shareholders will have a reason to smile today, with the analysts making substantial...Earnings Update: Philogen S.p.A. (BIT:PHIL) Just Reported And Analysts Are Boosting Their Estimates
Philogen S.p.A. ( BIT:PHIL ) last week reported its latest yearly results, which makes it a good time for investors to...What Philogen S.p.A.'s (BIT:PHIL) P/S Is Not Telling You
You may think that with a price-to-sales (or "P/S") ratio of 25.1x Philogen S.p.A. ( BIT:PHIL ) is a stock to avoid...Here's Why We're Watching Philogen's (BIT:PHIL) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...Rendement voor aandeelhouders
| PHIL | IT Biotechs | IT Markt | |
|---|---|---|---|
| 7D | 5.9% | 4.7% | 2.8% |
| 1Y | 4.0% | 33.3% | 20.1% |
Rendement versus industrie: PHIL presteerde slechter dan de Italian Biotechs -sector, die het afgelopen jaar een rendement van 33.3 % opleverde.
Rendement versus markt: PHIL presteerde slechter dan Italian Market, dat het afgelopen jaar een rendement van 20.1 % opleverde.
Prijsvolatiliteit
| PHIL volatility | |
|---|---|
| PHIL Average Weekly Movement | 4.2% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IT Market | 8.5% |
| 10% least volatile stocks in IT Market | 3.2% |
Stabiele aandelenkoers: PHIL heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de Italian markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van PHIL is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1996 | 214 | Dario Neri | www.philogen.com |
Philogen S.p.A., een biotechnologiebedrijf, ontwikkelt geneesmiddelen voor oncologie en chronische ontstekingsziekten. Het ontwikkelt Nidlegy, een combinatie van de immunocytokines L19IL2 en L19TNF voor intralesionale behandeling van locoregionaal melanoom en niet-melanoom huidkanker; Fibromun, een humaan immunomodulerend product bestaande uit L19-antilichaam en TNF voor de behandeling van weke delen sarcoom, leiomyosarcoom en glioom; en Darleukin (L19IL2), een menselijk immunostimulerend product bestaande uit het menselijke L19-antilichaam gefuseerd met het menselijke cytokine interleukine-2 (IL2), dat zich in fase II van het klinisch onderzoek bevindt voor de behandeling van niet-kleincellige longkanker. Het bedrijf ontwikkelt ook Dodekin, een humaan immunostimulerend product dat bestaat uit vasculair targeting antilichaam gefuseerd met interleukine-12 dat zich in fase I/II klinische studie bevindt voor de behandeling van vergevorderde vaste tumoren; Dekavil (F8IL10), een ontstekingsremmend product dat zich in fase II klinische studie bevindt voor de behandeling van chronische ontstekingsaandoeningen; Onco IX (PHC-102), een 99mTc gelabelde kleine molecule radiotracer voor de niet-invasieve detectie van koolzuuranhydrase IX (CAIX) dat tot expressie komt op het oppervlak van vaste tumoren, dat zich in fase 1 van de klinische studie bevindt; en OncoFAP, een kleine molecule radiotracer voor de niet-invasieve detectie van verschillende metastatische vaste tumoren gericht tegen fibroblast activatie proteïne, dat zich in fase 1 van de klinische studie bevindt.
Philogen S.p.A. Samenvatting
| PHIL fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | €942.58m |
| Inkomsten(TTM) | €229.68m |
| Inkomsten(TTM) | €319.73m |
Is PHIL overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| PHIL resultatenrekening (TTM) | |
|---|---|
| Inkomsten | €319.73m |
| Kosten van inkomsten | €39.57m |
| Brutowinst | €280.16m |
| Overige uitgaven | €50.49m |
| Inkomsten | €229.68m |
Laatst gerapporteerde inkomsten
Dec 31, 2025
Volgende inkomensdatum
Sep 23, 2026
| Winst per aandeel (EPS) | 5.70 |
| Brutomarge | 87.62% |
| Nettowinstmarge | 71.83% |
| Schuld/Eigen Vermogen Verhouding | 0.01% |
Hoe presteerde PHIL op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/25 06:08 |
| Aandelenkoers aan het einde van de dag | 2026/05/25 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Philogen S.p.A. wordt gevolgd door 4 analisten. 3 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Rajan Sharma | Goldman Sachs |
| Victor Floch | Stifel, Equities Research |
| Clemence Thiers | Stifel, Equities Research |